Zai Lab starts Phase 2 trial of ZL-1102 to treat CPP

Zai Lab Limited announced that the first patient has been dosed in a global Phase 2 clinical trial, NCT06380907, evaluating the efficacy and safety of the company’s internally developed anti-IL-17 investigational therapy, ZL-1102, for the treatment of chronic plaque psoriasis or CPP. ZL-1102 is a novel human VH antibody fragment, Humabody, targeting the IL-17 cytokine. Emphasizing its unique approach, ZL-1102 is being developed as a topical treatment for mild-to-moderate CPP, differentiating it from other anti-IL-17 products that target moderate-to-severe forms of the disease through systemic administration…”This study marks an important milestone in Zai’s evolution and is a testament to our outstanding internal R&D team’s commitment to develop novel therapies to help patients across the globe,” said Josh Smiley, President and Chief Operating Officer, Zai Lab.